83 related articles for article (PubMed ID: 29033198)
21. Fulminant vasculitis: a rare fatal complication of lymphoma.
Leshem E; Davidovitz Y; Meltzer E; Fefer P; Ofek E; Sidi Y
Acta Haematol; 2006; 115(1-2):117-22. PubMed ID: 16424662
[TBL] [Abstract][Full Text] [Related]
22. Indolent lymphomas.
Tura S; Zinzani PL
Haematologica; 2000 Feb; 85(2):113-4. PubMed ID: 10681715
[No Abstract] [Full Text] [Related]
23. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
24. Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM).
Chiappella A; Ciochetto C; Orsucci L; Vitolo U
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):149-51. PubMed ID: 21454219
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas.
Forsyth CJ; Gomez-Almaguer D; Camargo JF; Eliadis PE; Crespo-Solis E; Pereira J; Gutierrez-Aguirre CH; Rivas-Vera S; Roberson S; Lin B; Smith NV; Hamid O
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):398-403. PubMed ID: 23770158
[TBL] [Abstract][Full Text] [Related]
26. Bar the windows but open the door to randomization.
Ratain MJ
J Clin Oncol; 2010 Jul; 28(19):3104-6. PubMed ID: 20516430
[No Abstract] [Full Text] [Related]
27. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
Pagel JM; Spurgeon SE; Byrd JC; Awan FT; Flinn IW; Lanasa MC; Eisenfeld AJ; Stromatt SC; Gopal AK
Br J Haematol; 2015 Jan; 168(1):38-45. PubMed ID: 25146490
[TBL] [Abstract][Full Text] [Related]
28. [Residual masses after treatment of non-Hodgkin's lymphoma: interpretation of a case of gastric lymphoma].
Baena Cañada JM; Moreno Nogueira JA
An Med Interna; 1991 Nov; 8(11):572. PubMed ID: 1790288
[No Abstract] [Full Text] [Related]
29. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
30. [PRIMARY VAGINAL NON-HODGKIN LYMPHOMA--A CASE REPORT AND REVIEW FROM THE LITERATURE].
Jordanov A; Hinkova N; Ivanov I; Popovska S
Akush Ginekol (Sofiia); 2015; 54(5):47-8. PubMed ID: 26411197
[TBL] [Abstract][Full Text] [Related]
31. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Breccia M; Martelli M; Cannella L; Russo E; Finolezzi E; Stefanizzi C; Levi A; Frustaci A; Alimena G
Leuk Res; 2008 Feb; 32(2):353-5. PubMed ID: 17825907
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
33. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
38. New therapies in non-Hodgkin lymphoma.
Novelli S; Sierra J; Briones J
Expert Rev Anticancer Ther; 2015 Mar; 15(3):349-59. PubMed ID: 25582186
[TBL] [Abstract][Full Text] [Related]
39. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
Specht L
Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
[TBL] [Abstract][Full Text] [Related]
40. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
O'Connor OA; Portlock C; Moskowitz C; Straus D; Hamlin P; Stubblefield M; Dumetrescu O; Colevas AD; Grant B; Zelenetz A
Br J Haematol; 2008 Oct; 143(2):201-9. PubMed ID: 18691173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
